PURPOSE: To establish optimum conditions for anti- @entity5 therapy, we evaluated the efficacy of @entity632 using liposomal @entity632 and local @entity221 to improve the anti- @entity5 efficacy over liposomal @entity632 alone in @entity95 VX2 @entity5 . MATERIALS AND METHODS: A VX2 @entity5 model was established in New Zealand white @entity95 , which were randomly divided into five groups: 1) control, 2) free @entity632 ( @entity3105 ), 3) liposomal @entity632 (L- @entity3105 ), 4) L- @entity3105 plus 41     C thermotherapy (L- @entity3105   +   41     C TT); and 5) L- @entity3105 plus 43     C thermotherapy (L- @entity3105   +   43     C TT). To achieve complete @entity5 remission, multiple high-dose administrations (5   mg/kg, once per week for a total of 3 weeks) were given. An ultrasound @entity221 instrument was used to induce local @entity221 and the systemic @entity137 of @entity3105 was evaluated by changes in weight, blood count and serum lactic dehydrogenase. The anti- @entity5 effect of @entity3105 was evaluated by observing the gross @entity5 volume, weight and @entity95 survival. RESULTS: The white blood cell count following administration of @entity3105 or L- @entity3105 was lower than for control animals and those treated with L- @entity3105   +   41     C TT. There was no difference between the groups with regard to the red blood cell count. Compared with the control and @entity3105 groups, @entity5 proliferation was significantly inhibited following administration of L- @entity3105 , L- @entity3105   +   41     C TT and L- @entity3105   +   43     C TT, as evidenced by the difference in @entity5 volume, weight and survival time. Differences in @entity5 proliferation were also found between the L- @entity3105 and thermotherapy groups. CONCLUSION: Local @entity221 combined with L- @entity3105 can significantly improve anti- @entity5 efficacy and reduce systemic @entity137 .

The efficacy and hyperthermic release of @entity632 from liposomal @entity632 in XXXX VX2 @entity5 .

@entity632 :: ('MESH:D004317', 'Chemical') :: ['doxorubicin', 'doxorubicin hydrochloride'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumours', 'tumour'] @entity95 :: ('9986', 'Species') :: ['rabbits', 'rabbit'] @entity3105 :: ('D004317', 'Chemical') :: ['Dox'] @entity221 :: ('MESH:D005334', 'Disease') :: ['hyperthermia']
@entity95 :: (9986,Species) :: ['rabbit']
